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Active surveillance (AS) is a possible new approach for men
with very low-risk and low-risk prostate cancer (PCa) and, less
frequently, those with intermediate-risk PCa as a way to reduce
overtreatment of clinically indolent disease (1-3). The very low
likelihood of progression of this disease to unfavorable
outcomes in appropriately selected men has demonstrated that
AS can be used with good outcomes (4,5). High cancer-specific
survival rates have been described, reaching 94.3% and 99.9%
at the University of Toronto and Johns Hopkins Hospital,
respectively (4,5), during 15 years of follow-up. Data from
Sweden and the United States have shown cancer-specific
survival rates of 60% and 64%, respectively, in patients who
participated in AS after 5 years (6,7), and 55% cancer-specific
survival has been reported in Canada after 15 years (4).
Despite good outcomes with AS, the poorly defined criteria
for intervention and the lack of standardized surveillance
protocols are important limitations. In all protocols for AS
around the world, systematic transrectal ultrasound (TRUS)-
guided biopsy is the tool used to establish a diagnosis of PCa
(8), but the morbidity associated with this method is well
known and can range from local symptoms, such as hematuria
and acute urinary retention, to systemic symptoms, such as
bacteremia and sepsis. Each new biopsy greatly increases the
complication rates (9).
Another issues related to AS is the underestimation of the
real extent of the disease and aggressiveness based only on
standard biopsy (SB) data. Approximately thirty percent of
patients with low-risk PCa on initial biopsy have a Gleason
score upgrade when treated by radical prostatectomy; thus,
SB is associated with substantial misclassification that may
lead to inappropriate selection of patients for AS and postpone-
ment of the necessary treatment (10). Therefore, distinction of
patients who have low-risk cancers and those who need
immediate treatment is a serious challenge. In this scenario,
multiparametric magnetic resonance imaging (mpMRI) has
appeared as a promising imaging modality to help to better
select and manage patient candidates for AS (11-13).
Currently, many studies confirmed that mpMRI is a use-
ful instrument for detecting clinically significant PCa. The
sensitivity is 86% for identifying tumors greater than 0.5 cm3
in size (14) and 80% for detecting index tumors (15). How-
ever, the precise role of mpMRI in AS is not yet well
established. Defining the role of mpMRI during the initial
diagnosis and follow-up of patients undergoing AS is the
next step.
mpMRI
In recent years, rapid technological advances have taken
place. Thus, the acquisition of high quality images has
advanced the current knowledge about the findings of PCa
on mpMRI. Exam standardization and a high level of reader
training have made mpMRI an important tool in PCa man-
agement in daily practice. Usually, the exam is performed
by a 3-Tesla scanner; however, a 1.5-Tesla magnet with an
endorectal coil can be used to perform diffusion weighted
imaging (DWI), T2-weighted imaging (T2WI) and dynamic
contrast-enhanced MRI (DCE-MRI) (16).
The famous Prostate Imaging Reporting and Data System
version 2 (PI-RADS), which is frequently used in the descrip-
tion of PCa, was developed to standardize MRI reporting.
PI-RADS can be used to generate a map of the prostate to
define the area of interest (17). Suspicious lesions are graded
on a 5-point scale based on features suggestive of malig-
nancy, and the probability of clinically significant PCa is
related to a higher PI-RADS grade. The lesion with highest
PI-RADS category if there is more than one lesion or the
largest lesion when the lesions have same PI-RADS grade is
considered the index lesion.
Certain characteristics of the parameters of T2WI, DWI
and DCE-MRI aid in disease diagnosis. Currently, the use of
DCE-MRI has low applicability. DCE-MRI is used only for
lesions in in situ irradiated glands in which an enhancing
nodule is strongly suggestive of PCa or to separate PI-RADS
3 and 4 lesions in the peripheral zone. Greer et al. demon-
strated a high positive predictive value for PI-RADSX3 and
X4 lesions (85% and 90%, respectively) to detect clinically
significant cancer with PI-RADS 2.0 (18) (Figure 1).DOI: 10.6061/clinics/2018/e464s
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Figure 1 - DWI is better than T2WI in the peripheral zone, and T2WI is better than DWI in the transitional zone. The DCE-MRI
determines the final PI-RADS score when PI-RADS 3 is present in the peripheral zone. DWI determines the final PI-RADS score when
PI-RADS 3 is present in the transitional zone.
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Candidate selection for AS and the role of mpMRI
There are several AS protocols described in the literature
with different inclusion criteria, and the lack of uniformity
among these protocols poses the first challenge in clinical
practice (Table 1). The most frequently used criteria to include
patients in AS are Gleason score p3+3, prostate-specific
antigen (PSA) p10 ng/mL, clinical stage pT2, maximum of
2 positives cores or p50% per core. Two important excep-
tions are the groups from Memorial Sloan-Kettering Cancer
Center who admitted patients with up to three involved
cores and the group from Toronto who admitted patients
with Gleason scores up to 7 (3+4) and with PSA levels up to
15 ng/mL. When the patients do not fulfill all these criteria,
they cannot be included in AS because are deemed to have
clinically significant disease. The problem with AS is that
conventional prostate biopsy undersamples roughly one-third
of patients when compared with prostatectomy specimens
(20). mpMRI can yield important details about the disease
since this modality detects with higher accurately tumors
with Gleason score higher than 6 and has a higher sensitivity
than computed tomography for detecting extracapsular
extension thus decreasing the undergrading and under-
staging rates. However, in the majority of AS programs,
mpMRI findings are not adopted as initial inclusion criteria.
Currently, mpMRI has helped in the early detection and
staging of PCa. Many studies have demonstrated that the
incorporation of mpMRI findings during the initial diag-
nosis of PCa has better accuracy than TRUS findings
(21,22). If MRI shows a suspected lesion, these patients
must undergo image-guided fusion biopsies. There are
three possible modalities that can be used to perform this
procedure: in-bore MR fusion, cognitive fusion, and finally,
MR-US software fusion biopsy (16). Overall cancer detec-
tion is significantly higher when MR-US software is used
to generate the fusion image (48.1%) than when cognitive
fusion alone is used (34.6%) (p=0.04) (23).
Table 1 - Active surveillance protocols. Inclusion criteria, monitoring and intervention criteria.
Cohort Selection criteria Monitoring protocol When to intervene
Johns Hopkins
Tosoian et al. (19)
2015
Gleason p 3 + 3
T1c
p2 positive cores
p50% involvement in any core
PSA density o0.15 ng/mL
DRE and PSA measurements (total and
free) every 6 months
Annual 12- to 14-core biopsy
Gleason 46
42 positive cores
450% involvement in any core
Sunnybrook
(Toronto)
Klotz et al. 2015
Low risk
Gleason 3 + 3
PSA o10 ng/mL
or
Favorable intermediate risk:
PSA 10-20 ng/mL
Gleason p3 + 4
3-monthly PSA for 2 years, then 6-monthly
Confirmatory biopsy within 12 months of
initial biopsy, then every 3 to 4 years until
age 80
PSA doubling time o3 years
Upgrade on repeat biopsy
Clinical progression on DRE
UCSF
Welty et al. 2015
PSA o10 ng/mL
T1 or T2
Gleason 3 + 3 or less
o33% positive cores
o50% cancer involvement in any core
PSA every 3 months
TRUS every 6 months
Annual 12-core sextant biopsies
Patient anxiety
Biopsy reclassification
Change in clinical stage
CAPRA risk reclassification
Australian
Thompson
et al. 2014
PSA o10 ng/mL
Stage oT2b on DRE
Gleason 3 + 3
o20% positive cores
o30% or 6 mm cancer in all positive cores
PSA every 3 months for 3 years then
6-monthly
DRE every 6 months for 3 years then
annually
Biopsies at 12- 24-36 months,
then every 3-5 years
Watchful waiting 475 years or life
expectancy o7 years
PSA doubling time o3 years
PSA velocity 40.75 ng/mL
DRE progression
Biopsy upgrade
Cancer volume progression
PRIAS
Bokhorst
et al. 2016
pGleason 3+3
pT2c
PSA o10 ng/ml
p2 positive cores
PSA density o0.2 ng/ml/cm2
or
Gleason p 3 + 4: o 10% involvement in
any core, p 2 positive cores if age 4 70
or
42 cores positive on MRI-target biopsy
15% involvement in core on saturation
biopsies
3-monthly PSA and 6-monthly
DRE for the first 2 years
6-monthly PSA and annual DRE thereafter
Standard biopsies at 1, 4, 7, and 10 years,
then every 5 years
Bone scan if PSA 420 ng/ml
42 positive cores
Gleason 4 3 + 3
Stage 4cT2
PSA doubling time o3 years
Criteria adapted for Gleason 3+ 4
and 42 cores based on MRI or
saturation biopsies
Royal Marsden
Selvadurai
et al. 2013
Gleason 3 + 3
Gleason 3 + 4 in patients 4 65
PSA o15 ng/ml
T1 or T2
PPC o50% of total number of biopsy cores
DRE and PSA every 3 months in the
first year
Every 4 months in the second year
Every 6 months thereafter
TRUS biopsy after 18-24 months and
then every 2 years
PSAV 41 ng/ml per year
Upgrade on repeat biopsy
3
CLINICS 2018;73(suppl 1):e464s Role of MRI in AS for prostate cancer
Cavalcante A et al.
Siddiqui et al. (24) recruited 1003 men with PCa who
underwent SB and targeted biopsy. This prospective study
showed that targeted biopsy had increased accuracy for high-
risk cancer, diagnosing 30% more cases (173 vs. 122 cases,
po0.001) and decreased accuracy for low-risk cancer, diagn-
osing 17 fewer cases (213 vs. 258 cases, po0.001). In a second
analysis evaluating targeted biopsy combined with SB, an
increase in the diagnosis of low-risk PCa with an additional
103 cases (22%) was observed. Among 170 patients who
underwent radical prostatectomy and were diagnosed with
whole-gland disease after pathologic analysis, the preopera-
tive targeted biopsy demonstrated better predictive ability to
differentiate low-risk, intermediate or high-risk tumors than
the two approaches used together or SB alone (0.73, 0.67 and
0.59, respectively, po0.05) (24).
Pessoa et al. (25) recently published a prospective cohort
study involving 105 patients on AS who underwent mpMRI
examinations. Reclassification rates among patients with
PI-RADS 1, 2, 3, 4, and 5 were 0%, 23.1%, 9.1%, 74.5%, and
100%, respectively. The overall reclassification rate was
55.2%, and the most frequent criterion change was Gleason
score classification (44.8%). Approximately 60% of the
population was PI-RADS 4 and 5 on mpMRI, and in this
group (PI-RADS grade 4 and 5), the rate of reclassification
was 85.71%. The sensitivity, specificity, positive predictive
value, and negative predictive value of mpMRI for disease
reclassification were 92.5%, 76%, 81%, and 90.5%, respectively.
These findings are comparable to what Lee et al. (26) found
at the Cleveland Clinic on prostate specimens from patients
who underwent radical prostatectomy for low-risk disease.
Other similar studies have been recently published. Da Rosa
et al. (27) from the University of Toronto, in a prospective
study, reported upgrading in 19 out of 72 patients on AS with
a Gleason score X7. Seven of these upgraded patients were
detected only on MR-fusion-targeted biopsy, two were detected
only on TRUS-guided systematic biopsy alone, and 10 were
detected using both techniques. The negative predictive value
for significant cancer approached 100% among men with
no suspicious lesions identified using mpMRI. Current data
from Memorial Sloan-Kettering (28) have been reported
regarding the reclassification rate of 206 men with low-risk
PCa enrolled in AS who underwent MR-fusion-targeted biopsy
and systematic prostate biopsy. MRI identified suspicious
lesions in 66% of patients, reinforcing that MRI findings have
the potential to alter the management of low-risk PCa patients.
In a retrospective study, Vargas et al. (13) found that
20% (79 of 388) of patients with clinically low-risk PCa had
Gleason scores upgraded on confirmatory biopsy. These patients
underwent MRI scans between the initial and confirmatory
biopsies. MRI scoresp2 had a high negative predictive value
(0.96-1.0) for upgrading on confirmatory biopsy, while a
score of 5 were highly sensitive for upgrading on confirma-
tory biopsy (0.87-0.98).
In summary, the use of mpMRI as initial screening exam
for PCa allows better stratification of the disease. The sen-
sitivity and predictive negative value of mpMRI are high,
both of which are important features for screening tests. MRI
fusion biopsy of target lesions has higher predictive negative
than TRUS-guided biopsy (29).
Role of mpMRI during follow-up of patients on AS
Once patients are selected to undergo AS, they are moni-
tored with PSA exams, digital rectal exams (DREs) and
standard prostate biopsies. Sometimes patients are followed
for many years and may require a considerable number of
biopsies. However, prostate biopsy is an invasive technique
and is associated with morbidity. The most common compli-
cations are pain, hematuria, hematospermia, erectile dys-
function, and infections. Thus, some recent studies have
demonstrated that mpMRI is a promising alternative to
decrease biopsies and thus prevent the complications related
to this method.
The true role of mpMRI for monitoring patients on AS is
not fully established; however, some studies suggest that
serial MRI scans improve prediction of pathological progres-
sion compared to clinicopathological variables alone, and
stable MRI findings are associated with pathological stabil-
ity (30-32). In the largest published retrospective study,
Frye et al. (33) analyzed 166 men with PCa on AS in whom
mpMRI-evident lesions were monitored, and fusion-guided
biopsy was properly indicated. The mean follow-up was
25.5 months, and pathologic progression was observed in
29.5% of patients. Targeted fusion biopsy identified progres-
sion in 44.9% of patients, and systematic biopsy detected
progression in 30.6% (p=0.03). Progression was observed
26% more frequently with fusion biopsy than with systema-
tic biopsy, and in this series, progression on mpMRI was
shown to be the sole predictor of pathological progression in
patients on AS (p=0.013). The analysis of pathologic progres-
sion on mpMRI in a cohort study demonstrated a negative
predictive value of 81%, a sensitivity of 77.6%, a positive
predictive value of 35% and a specificity of 40.5%. These
authors concluded that as imaging and technology evolve,
the number or frequency of biopsies in men on AS may
potentially be reduced (33).
In their cohort, Felker et al. (30), found that mpMRI had
low sensitivity (37%) but high specificity (90%) for predicting
pathologic progression. The main changes were maximum
cancer core length (MCCL) X3 mm at baseline biopsy and
prostate-specific antigen density (PSAD) X0.15 ng/ml at
follow-up biopsy. Overall, 19 patients had pathologic pro-
gression: 9 patients (47%) were identified on targeted biopsy,
7 (37%) on systematic biopsy, and 3 (16%) on systematic and
targeted biopsy, highlighting the importance of targeted
biopsies in patients on AS. In a similar study, Rosenkrantz
et al. (32) analyzed and compared the changes in prostate
index lesions identified on serial mpMRI with the follow-up
biopsy results of patients on AS. A total of 55 patients were
analyzed with median follow-up of 14 months; these authors
observed that MRI had a high specificity (76% to 90%) for
predicting positive follow-up biopsy results but a low sen-
sitivity (23% to 35%).
In 206 men selected for AS, Recabal et al. (28) noted that
66% had regions of interest on MRI, and 35% were upgraded.
They also found that when MRI-targeted biopsy was per-
formed, the increase in detection of higher grade cancer
was 23%; furthermore, the higher the PI-RADS score on MRI
was, the greater the likelihood of finding a high-grade tumor
(po0.0001).
Morgan et al. (34) published a pilot study with 50 patients
on AS who underwent mpMRI and compared the differences
in apparent diffusion coefficients (ADCs) in patients who
underwent radical prostatectomy and those who did not.
A 10% decrease in ADC designated progression with a
sensitivity of 93%. Thus, this study demonstrated that MRI
may be an effective tool for follow-up of patients with early
PCa on AS.
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Tran et al. (35) evaluated the utility of mpMRI fusion
biopsy for predicting disease progression in patients on AS
compared with systematic biopsy. They showed that 83 men
(40%) experienced upgrading including 49 (24%) who under-
went systematic sampling, 30 (14%) who underwent MRI-
targeted core biopsies, and 4 (2%) who underwent both.
Seven patients (9%) exhibited major upgrading with sys-
tematic biopsy among those with negative results on MRI-US
fusion biopsy.
Cost-effectiveness analysis of mpMRI during AS
An important point for deciding whether a method should
be used routinely in the investigation and follow-up of a
disease is whether this method has clinical applicability and
feasibility from an economic point of view. However, this
analysis becomes difficult since the cost of a specific exam
and its particularities, such as hospitalization, treatment of
complications and protocols for institutional execution of
the exams, are extremely variable around the world. A few
studies have attempted to analyze the cost-effectiveness of
mpMRI in patients on AS and the results have varied. The
methods and parameters used to evaluate cost-effectiveness
in these studies were not uniform; thus, making comparisons
of the results is not possible. The main points evaluated in
the cost-effectiveness analysis studies were the estimated
cost of the examination and the quality of life assessed by
quality-adjusted life years (QALYs). QUALYs is a generic
measure used in economic evaluation to assess the value for
money of medical interventions; one QUALY is equal to to
one year in perfect health and 0 QUALY indicates death.
European studies have had divergent results about the
cost-effectiveness of MRI for AS (36-38). In these studies,
the costs of MRI and TRUS were similar. Nicholson et al.
(36) showed that the use of MRI to follow-up patients with
PCa on AS was not cost-effective when compared with other
strategies. Two other studies demonstrated divergent results,
stating that MRI-based strategies were cost-effective (37,38).
Mowatt et al. (38) suggested that the use of MRI in the
patients studied was d7,685 below the threshold stipulated
by QUALY (d20,000 vs d12,315) calculated in order to be
considered cost-effective in the UK. In a study conducted in
the Netherlands, de Rooij et al. (37) also showed the cost-
effectiveness of strategies based on MRI.
In an Australian study, Gordon et al. (39) analyzed the
survival, total number of biopsies, healthcare costs, insignif-
icant and significant cancer and QUALYs in patients in 3
different scenarios: patients diagnosed by TRUS without
MRI and referred for radiotherapy, surgery or AS; patients
who underwent TRUS guided by MRI and referred for
radiotherapy, surgery or AS; and patients who underwent
TRUS guided by MRI who all underwent AS. After
separately analyzing the cost of the exam and QUALY, it
was not possible to state that an MRI was cost-effective in
patients with PCa in the current scenario of AS. However, it
is believed that if MRI is able to include more patients on AS
thus postponing radical treatment (surgery or radiotherapy),
this tool can become cost-effective. A recent study entitled
the ProstateMR Imaging Study (PROMIS) was conducted to
analyze the cost of diagnosing clinically significant (CS)
cancer by comparing MRI with TRUS findings in the UK
(40). The results showed that MRI as the first examination
detected more CS cancer per pound than TRUS (sensitivity
=0.95 [95% confidence interval (CI) 0.92-0.98] vs 0.91 [95% CI
0.86-0.94]) and was also cost-effective (ICER=d 7,076 [h8350 /
QALY gained]). Even though the PROMIS study did not aim
to evaluate cost-effectiveness in AS patients, we can infer that
this study has indirect applicability in the AS scenario, since
diagnosing patients with CS cancer earlier can lead to
exclusion or inclusion of these patients in AS programs.
Due to the wide divergence between studies in the anal-
ysis of the cost of MRI compared to TRUS or the cost-
effectiveness of these techniques used during AS, we cannot
extrapolate the results of one study to a location other than
where the study was conducted. In addition to cost variability
among exams, hospitalizations and procedures worldwide,
the lack of uniformity in the protocols used for AS make it
difficult to standardize cost-effectiveness studies. Thus, at
this time, it is not possible to make final statements about the
cost-effectiveness of MRI in the AS scenario. Individualized
studies for the given reality in which the use of mpMRI is
desired to be evaluated seem to be the best option for a more
reliable analysis of cost-effectiveness.
Current data show that mpMRI is an adjunctive power-
ful tool that can assist in the selection of patients for AS,
increasing the diagnostic accuracy of prostate biopsy. The
integration of mpMRI data and the combination of targeted
biopsy and systematic biopsy improve detection of higher
grade disease thus decreasing incorrect patient selection for
AS. Therefore, we believe that MRI findings should be used
as additional criteria for inclusion of patients in future pro-
tocols for AS. The role of MRI in the follow-up of patients
on AS is not yet well established. Recent data support that
MRI should not be used as an autonomous tool to follow-up
and trigger biopsies because upgrading also occur in areas
outside the targeted biopsy, but improved definition and
standardization of radiological progression for patients on
AS is expected.
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